Acquisition, transmission and amplification of drug-resistant tuberculosis

Progress in Respiratory Research

Volumn 40, Issue , 2011, Pages 96-104

  Müller, Borna ^a   Warren, Robin M ^a   Williams, Monique ^a   Böttger, Erik C ^b   Gey Van Pittius, Nicolaas C ^a   Victor, Thomas C ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052930573     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000324624     Document Type: Article

References (54)

1. Nguyen L, Pieters J: Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: Challenges in tuberculosis drug development. Annu Rev Pharmacol Toxicol 2009; 49:427-453.
2. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T: Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010;201:1225-1231.
3. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, van Helden PD, Victor TC: A balancing act: Efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009;53: 3181-3189.
4. World Health Organization: Guidelines for Surveillance of Drug Resistance in Tuberculosis. Geneva, WHO, 2009.
5. Bottger EC, Springer B: Tuberculosis: Drug resistance, fitness, and strategies for global control. Eur J Pediatr 2008;167:141-148.
6. Johnson R, Streicher EM, Louw GE, Warren RM, van Helden PD, Victor TC: Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006;8:97-111.
7. Barnard M, Allbert H, Coetzee G, O'Brien R, Bosiman ME: Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177:787-792. (Pubitemid 351490566)
8. Van Deun A, Martin A, Palomino JC: Diagnosis of drug-resistant tuberculosis: Reliability and rapidity of detection. Int J Tuberc Lung Dis 2010;14:131-140.
9. Zhang Y, Yew WW: Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13:1320-1330.
10. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB: Tuberculosis drug resistance mutation database. PLoS Med 2009;6:e2.
11. Jassal M, Bishai WR: Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009;9:19-30.
12. Hoek KG, Schaaf HS, Gey van Pittius NC, van Helden PD, Warren RM: Resistance to pyrazinamide and ethambutol compromises MDR/XDRTB treatment. S Afr Med J 2009;99:785-787.
13. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, Liversage T, Masibi M, van Helden PD, Warren RM, Victor TC: Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010;16:264-271.
14. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-1580. (Pubitemid 44780738)
15. World Health Organization: Treatment of Tuberculosis -Guidelines. Geneva, WHO, 2009.
16. Medical Research Council: Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;ii:769-782.
17. Dunner E, Brown WB, Wallace J: The effect of streptomycin with para-aminosalicylic acid on the emergence of resistant strains of tubercle bacilli. Dis Chest 1949;16:661-666.
18. Medical Research Council: Treatment of pulmonary tuberculosis with streptomycin and paraamino-salicylic acid. Br Med J 1950;ii:1073-1085.
19. Gillespie SH: Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective. Antimicrob Agents Chemother 2002;46:267-274. (Pubitemid 34087167)
20. David HL: Probability distribution of drugresistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970;20:810-814.
21. Donald PR, van Helden PD: The global burden of tuberculosis -combating drug resistance in difficult times. N Engl J Med 2009;360:2393-2395.
22. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG: Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-1202. (Pubitemid 34297782)
23. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K: HIV infection and multidrug-resistant tuberculosis: The perfect storm. J Infect Dis 2007;196(suppl 1):S86-S107. (Pubitemid 47206088)
24. Victor TC, Streicher EM, Kewley C, Jordaan AM, van der Spuy GD, Bosman M, Louw H, Murray M, Young D, van Helden PD, Warren RM: Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. Int J Tuberc Lung Dis 2007;11:195-201. (Pubitemid 46219284)
25. Johnson R, Warren R, Strauss OJ, Jordaan AM, Falmer AA, Beyers N, Schaaf HS, Murray M, Cloete K, van Helden PD, Victor TC: An outbreak of drug-resistant tuberculosis caused by a Beijing strain in the Western Cape, South Africa. Int J Tuberc Lung Dis 2006;10:1412-1414. (Pubitemid 44924598)
26. Van Rie A, Warren RM, Beyers N, Gie RP, Classen CN, Richardson M, Sampson SL, Victor TC, van Helden PD: Transmission of a multidrugresistant Mycobacterium tuberculosis strain resembling 'strain W' among noninstitutionalized, human immunodeficiency virusseronegative patients. J Infect Dis 1999;180:1608-1615. (Pubitemid 29506465)
27. Johnson R, Warren RM, van der Spuy GD, Gey van Pittius NC, Theron D, Streicher EM, Bosman M, Coetzee GJ, van Helden PD, Victor TC: Drugresistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int J Tuberc Lung Dis 2010;14:119-121.
28. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR: Transmission of tuberculosis in New York City -an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710-1716.
29. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-526. (Pubitemid 23053827)
30. Valway SE, Greifinger RB, Papania M, Kilburn JO, Woodley C, Di Ferdinando GT, Dooley SW: Multidrug-resistant tuberculosis in the New York State prison system, 1990-1991. J Infect Dis 1994;170:151-156. (Pubitemid 24186438)
31. The World Health Organization/International Union against Tuberculosis and Lung Disease (WHO/UNION) Global Project on Anti-Tuberculosis Drug Resistance Surveillance: Anti-Tuberculosis Drug Resistance in the World. Geneva, WHO, 2008.
32. Caminero JA: Multidrug-resistant tuberculosis: Epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010;14:382-390.
33. March F, Garriga X, Rodriguez P, Moreno C, Garrigo M, Coll P, Prats G: Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 1997;25:1044-1047. (Pubitemid 27513183)
34. Han LL, Sloutsky A, Canales R, Naroditskaya V, Shin SS, Seung KJ, Timperi R, Becerra MC: Acquisition of drug resistance in multidrugresistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005;9:818-821. (Pubitemid 41139138)
35. Cohen T, Lipsitch M, Walensky RP, Murray M: Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci USA 2006;103:7042-7047.
36. Middlebrook G: Isoniazid-resistance and catalase activity of tubercle bacilli: A preliminary report. Am Rev Tuberc 1954;69:471-472.
37. Middlebrook G, Cohn ML: Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953;118:297-299.
38. Borrell S, Gagneux S: Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13:1456-1466.
39. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ: The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006;312:1944-1946. (Pubitemid 43993719)
40. Gagneux S, Burgos MV, Deriemer K, Enciso A, Munoz S, Hopewell PC, Small PM, Pym AS: Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006;2:603-610.
41. Cohen T, Murray M: Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004;10:1117-1121. (Pubitemid 39424874)
42. Pym AS, Saint-Joanis B, Cole ST: Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002;70:4955-4960.
43. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Bottger EC: Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010, E-pub ahead of print.
44. Portugal I, Covas MJ, Brum L, Viveiros M, Ferrinho P, Moniz-Pereira J, David H: Outbreak of multiple drug-resistant tuberculosis in Lisbon: Detection by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 1999;3:207-213. (Pubitemid 29133045)
45. World Health Organization: Global Tuberculosis Control 2009 -Epidemiology, Strategy, Financing. Geneva, WHO, 2009.
46. Müller B, Streicher EM, Hoek KG, Tait M, Trollip A, Bosman ME, Coetzee GJ, Chabula-Nxiweni EM, Hoosain E, Gey van Pittius NC, Victor TC, van Helden PD, Warren RM: InhA promoter mutations: A gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis 2011;15:344-351.
47. Colangeli R, Helb D, Sridharan S, Sun J, Varma-Basil M, Hazbon MH, Harbacheuski R, Megjugorac NJ, Jacobs WR Jr, Holzenburg A, Sacchettini JC, Alland D: The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 2005;55: 1829-1840. (Pubitemid 40445216)
48. Van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD: Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-1179. (Pubitemid 29480655)
49. Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K: Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006;10:649-655. (Pubitemid 43845026)
50. Van Rie A, Victor TC, Richardson M, Johnson R, van der Spuy GD, Murray EJ, Beyers N, Gey van Pittius NC, van Helden PD, Warren RM: Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005;172: 636-642. (Pubitemid 41232977)
51. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM: The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009;106:14711-14715.
52. Ben AY, Nemser B, Singh A, Sankin A, Schluger N: Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis 2008; 14:1345-1352.
53. Strauss OJ, Warren RM, Jordaan A, Streicher EM, Hanekom M, Falmer AA, Albert H, Trollip A, Hoosain E, van Helden PD, Victor TC: Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J Clin Microbiol 2008;46:1514-1516. (Pubitemid 351563605)
54. Warren RM, Streicher EM, van Pittius NC, Marais BJ, van der Spuy GD, Victor TC, Sirgel F, Donald PR, van Helden PD: The clinical relevance of mycobacterial pharmacogenetics. Tuberculosis (Edinb) 2009;89:199-202.